An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Mirum Pharmaceuticals to Participate in September Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) announced its participation in five investor conferences during September 2021. Key events include the Citi 16th Annual BioPharma Virtual Conference on September 10, and the H.C. Wainwright Global Investor Conference from September 13-14, featuring a company presentation. Additional conferences include the Baird Global Healthcare Conference, the Leerink CyberRX Series 1x1 Event, and the Cantor Global Healthcare Conference. Mirum focuses on innovative therapies for liver diseases, with its lead candidate, maralixibat, under FDA priority review.
Positive
None.
Negative
None.
FOSTER CITY, Calif.--(BUSINESS WIRE)--
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will participate in five investor conferences taking place virtually throughout the month of September.
Citi 16th Annual BioPharma Virtual Conference September 10, 2021 Format: One-on-one meetings
H.C. Wainwright 23rd Annual Global Investor Conference September 13-14, 2021 Format: Company presentation (available September 13 at 7:00 a.m. ET) and one-one-meetings.
Baird Global Healthcare Conference September 14-15, 2021 Format: Company presentation (September 14 at 12:50 p.m. ET) and one-on-one meetings.
Leerink CyberRX Series 1x1 Event
September 22-23, 2021 Format: One-on-one meetings.
Cantor Global Healthcare Conference September 27-29, 2021 Format: Company presentation (September 27 at 2:40 p.m. ET) and one-on-one meetings.
Visit the Investors and Media section of Mirum’s corporate website for additional information.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Mirum’s lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia. Mirum has submitted an NDA for maralixibat in the treatment of cholestatic pruritus in patients with ALGS. The NDA has been accepted for priority review by the FDA with a PDUFA action date of September 29, 2021. Additionally, Mirum’s marketing authorization application for the treatment of pediatric patients with PFIC2 has been accepted for review (validated) by the European Medicines Agency. Mirum is also developing volixibat, also an oral ASBT-inhibitor, in primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, and primary biliary cholangitis. For more information, visit MirumPharma.com.
To augment its pipeline in cholestatic liver disease, Mirum has acquired the exclusive option to develop and commercialize gene therapy programs VTX-803 and VTX-802 for PFIC3 and PFIC2, respectively, from Vivet Therapeutics SAS, following preclinical evaluation and investigational new drug-enabling studies.
What investor conferences is MIRM attending in September 2021?
Mirum Pharmaceuticals will participate in five investor conferences throughout September 2021, including the Citi 16th Annual BioPharma Virtual Conference, H.C. Wainwright Global Investor Conference, Baird Global Healthcare Conference, Leerink CyberRX Series 1x1 Event, and Cantor Global Healthcare Conference.
When is the FDA PDUFA action date for MIRM's maralixibat?
The FDA PDUFA action date for Mirum Pharmaceuticals' maralixibat is September 29, 2021.
What is the purpose of MIRM's company presentations at these conferences?
The company presentations at the conferences aim to provide updates on Mirum Pharmaceuticals' pipeline and engage with potential investors.
What diseases does MIRM's maralixibat target?
Maralixibat is being developed to treat Alagille syndrome, progressive familial intrahepatic cholestasis, and biliary atresia.
What are VTX-803 and VTX-802 related to MIRM?
VTX-803 and VTX-802 are gene therapy programs for PFIC3 and PFIC2, respectively, that Mirum Pharmaceuticals has acquired an exclusive option to develop.
